Volume | 307,608 |
|
|||||
News | - | ||||||
Day High | 3.30 | Low High |
|||||
Day Low | 3.10 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Acumen Pharmaceuticals Inc | ABOS | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
3.24 | 3.10 | 3.30 | 3.15 | 3.16 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
3,494 | 307,608 | US$ 3.18 | US$ 979,222 | - | 1.8101 - 11.3099 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:40:17 | 5 | US$ 3.10 | USD |
Acumen Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
181.84M | 57.91M | - | 0 | -42.86M | -0.74 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Acumen Pharmaceuticals News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ABOS Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 3.85 | 3.93 | 3.10 | 3.38 | 281,848 | -0.70 | -18.18% |
1 Month | 4.33 | 4.43 | 3.10 | 3.81 | 334,186 | -1.18 | -27.25% |
3 Months | 3.27 | 5.09 | 2.8949 | 3.81 | 343,756 | -0.12 | -3.67% |
6 Months | 3.56 | 5.09 | 1.8101 | 3.19 | 454,827 | -0.41 | -11.52% |
1 Year | 3.53 | 11.3099 | 1.8101 | 5.72 | 574,334 | -0.38 | -10.76% |
3 Years | 25.07 | 26.98 | 1.8101 | 7.34 | 421,018 | -21.92 | -87.44% |
5 Years | 25.07 | 26.98 | 1.8101 | 7.34 | 421,018 | -21.92 | -87.44% |
Acumen Pharmaceuticals Description
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what we believe to be a key underlying cause of Alzheimer's disease. The company's lead drug candidate, ACU193, is a subclass monoclonal antibody which selectively targets amyloid-beta oligomers. |